Table 2.
Randomized trials assessing the combination of oxaliplatin and capecitabine in the first line treatment of metastatic colorectal cancer
| Authors | Regimen | No. patients | RR (%) | Median PFS (months) | Median OS (months) |
|---|---|---|---|---|---|
| Porschen et al23 | Oxaliplatin 70 mg/m2 d 1 and 8, capecitabine
1000 mg/m2 twice daily d 1–14 q 3 wks |
241 | 48% | 7.1
HR = 1.17 |
16.8
HR = 1.12 |
| p = 0.7 | p = 0.117 | p = 0.26 | |||
| Oxaliplatin 50 mg/m2, LV 500 mg/m2 + 5FU
2000 mg/m2 (22-h infusion) weekly × 4 q 6 wks |
233 | 54% | 8.0 | 18.8 | |
| Díaz-Rubio et al24 | Oxaliplatin 130 mg/m2 d 1, capecitabine
1000 mg/m2 twice daily d 1–14 q 3 wks |
171 | 37% | 8.9
HR = 1.18 |
18.1
HR = 1.22 |
| p = 0.539 | p = 0.153 | p = 0.145 | |||
| Oxaliplatin 85 mg/m2 d 1 biweekly, 5FU
2250 mg/m2 d 1 (48-h infusion) weekly |
171 | 46% | 9.5 | 20.8 | |
| Comella et al25 | Oxaliplatin 100 mg/m2 d 1, capecitabine
1000 mg/m2 twice daily d 1–11, q 2 wks |
158 | 34% | 6.6
HR = 1.12 |
16.0
HR = 1.0 |
| p = 0.999 | p = 0.354 | p = 0.883 | |||
| Oxaliplatin 85 mg/m2 d 1, 6S-LV 250 mg/m2 + 5FU 850 mg/m2 (bolus) d 2, q 2 wks | 164 | 33% | 6.5 | 17.1 | |
| Cassidy et al26 | Oxaliplatin 130 mg/m2 d 1, capecitabine
1000 mg/m2 twice daily d 1–14 q 3 wks ± bevacizumab |
1,017 | 37% | 8.0
HR = 1.04 (0.93–1.16) |
19.8
HR = 0.99 (0.88–1.12) |
| Oxaliplatin 85 mg/m2 d 1, LV 200 mg/m2+ 5FU 400 mg/m2 (bolus) and 600 mg/m2(22-h infusion) d 1 and 2 q 2 wks ± bevacizumab | 1,017 | 37% | 8.5 | 19.6 |
Abbreviations: HR, hazard ratio; PFS, progression-free survival; OS, overall survival.